Volume 29, Number 11—November 2023
CME ACTIVITY - Synopsis
Campylobacter fetus Invasive Infections and Risks for Death, France, 2000–2021
Table 4
Variable | Total, n = 21 | Survival, n = 14 | Death, n = 7 | p value† | OR (95% CI) |
---|---|---|---|---|---|
Dyspnea, respiratory rate >22 cycles/min |
7/21 (33) |
2/14 (14) |
5/7 (71) |
0.017 |
15.0 (1.9–186.4) |
qSOFA score | 0.017 | NA | |||
0 | 12/21 (57) | 11/14 (79) | 1/7 (14) | ||
1 | 2/21 (10) | 1/14 (7.1) | 1/7 (14) | ||
2 | 6/21 (24) | 2/14 (14) | 4/7 (57) | ||
3 |
1/21 (4.8) |
0/14 |
1/7 (14) |
||
qSOFA score | 0.012 | 4.9 (1.6–21.9) | |||
Sepsis: qSOFA score >2 | 7/21 (33) | 2/14 (14) | 5/7 (71) | 0.021 | 13.7 (1.7–171.4) |
Septic shock | 4/21 (19) | 0/14 | 4/7 (57) | 0.006 | NA |
Transfer to intensive care |
4/21 (19) |
0/14 |
4/7 (57) |
0.006 |
NA |
Treated with amoxicillin/clavulanic acid |
10/21 (48) |
9/14 (64) |
1/7 (14) |
0.05 |
0.09 (0.0–0.75) |
Antimicrobial drugs/patient | 0.001 | NA | |||
0 | 3/21 (14) | 0/14 | 3/7 (43) | ||
1 | 6/21 (29) | 5/14 (36) | 1/7 (14) | ||
2 | 8/21 (38) | 8/14 (57) | 0/7 | ||
3 |
4/21 (19) |
1/14 (7.1) |
3/7 (43) |
||
Antimicrobial drugs/patient, median | 1.6 | 1.7 | 1.4 | 0.519 | 0.7 (0.2–1.9) |
Infection-related mortality | 5/21 (24) | 0/14 | 5/7 (71) | 0.001 | NA |
*Values are no./total (%) except as indicated. Blank cells for p values indicate no p value was calculated. qSOFA, quick sequential organ failure assessment; NA, not applicable; OR, odds ratio. †p<0.05 indicates significance.
Page created: September 06, 2023
Page updated: October 17, 2023
Page reviewed: October 17, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.